The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.
Thomas G. Martin
No relevant relationships to disclose
Karl Hsu
Employment or Leadership Position - Sanofi
Stephen Anthony Strickland
No relevant relationships to disclose
Martha Jane Glenn
No relevant relationships to disclose
Joseph Mikhael
Research Funding - Celgene; Onyx; Sanofi
Eric Charpentier
Employment or Leadership Position - Sanofi